Icon (NASDAQ:ICLR) CFO Nigel Bernard John Clerkin Sells 1,488 Shares of Stock

Icon Plc (NASDAQ:ICLR) CFO Bernard Clerkin sold 1,488 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $206.66, for a total transaction of $307,510.08. Following the completion of the transaction, the chief financial officer directly owned 7,171 shares in the company, valued at approximately $1,481,958.86. The trade was a 17.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nigel Bernard John Clerkin also recently made the following trade(s):

• On Tuesday, August 11th, Bernard Clerkin sold 2,267 shares of Icon stock. The stock was sold at an average price of $164.29, for a total transaction of $372,445.43.

Icon Stock Down 0.7%

Shares of NASDAQ:ICLR traded down $1.37 on Tuesday, reaching $203.77. The company had a trading volume of 1,096,464 shares, compared to its average volume of 1,264,512. The firm’s 50 day simple moving average is $172.62 and its 200-day simple moving average is $146.63. The company has a current ratio of 1.32, a quick ratio of 0.95 and a debt-to-equity ratio of 0.37. Icon Plc has a 52-week low of $66.57 and a 52-week high of $219.04. The firm has a market capitalization of $15.60 billion, a PE ratio of 35.07, a PEG ratio of 13.65 and a beta of 1.24.

Icon (NASDAQ:ICLR) last posted its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.04. The firm had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Icon had a net margin of 5.45% and a return on equity of 7.73%. The business’s revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.31 EPS. As a group, analysts expect that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ICLR shares. Royal Bank Of Canada upped their target price on shares of Icon from $185.00 to $226.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. TD Cowen lifted their price target on Icon from $197.00 to $254.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Robert W. Baird raised their target price on shares of Icon from $210.00 to $249.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Truist Financial raised their price objective on shares of Icon from $209.00 to $268.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $254.00 price objective on shares of Icon in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $213.76.

Institutional Investors Weigh In On Icon

A number of hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Icon in the 3rd quarter worth about $38,000. GAMMA Investing LLC raised its holdings in shares of Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after acquiring an additional 69 shares in the last quarter. Fifth Third Bancorp raised its holdings in Icon by 1,062.0% during the 1st quarter. Fifth Third Bancorp now owns 918 shares of the medical research company’s stock valued at $102,000 after buying an additional 839 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of Icon by 120.0% during the second quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company’s stock worth $107,000 after purchasing an additional 336 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in Icon by 804.8% during the 1st quarter. Bessemer Group Inc. now owns 1,312 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 1,167 shares during the period. 95.61% of the stock is currently owned by institutional investors.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.